Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 10

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 10
---
 accelerated filer, as defined in the Securities Exchange
Act of 1934, as amended (the “Exchange Act”).

We are also a “smaller reporting company”
as defined in the Exchange Act and have elected to take advantage of certain of the scaled disclosures available to smaller reporting
companies. To the extent that we continue to qualify as a “smaller reporting company” as such term is defined in Rule 12b-2
under the Exchange Act, after we cease to qualify as an EGC, certain of the exemptions available to us as an EGC may continue to be available
to us as a “smaller reporting company,” including exemption from compliance with the auditor attestation requirements pursuant
to the Sarbanes-Oxley Act of 2002 (“SOX”) and reduced disclosure about our executive compensation arrangements. We will continue
to be a “smaller reporting company” until we have $250 million or more in public float (based on our Common Stock) measured
as of the last business day of our most recently completed second fiscal quarter or, in the event we have no public float (based on our
Common Stock) or a public float (based on our Common Stock) that is less than $700 million, annual revenues of $100 million or more during
the most recently completed fiscal year.

We may choose to take advantage of some, but not all,
of the available exemptions. We have taken advantage of certain reduced reporting obligations in this prospectus. Accordingly, the information
contained herein may be different than the information you receive from other public companies in which you hold stock. In addition, the
JOBS Act provides that an EGC may take advantage of an extended transition period for complying with new or revised accounting standards,
delaying the adoption of these accounting standards until they would apply to private companies. We have elected to avail ourselves of
the extended transition period for complying with new or revised financial accounting standards. As a result of the accounting standards
election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that
are not EGCs which may make comparison of our financials to those of other public companies more difficult.

Summary of Risk Factors

Like any emerging growth company, we face significant
risk factors that may impede our plans for successful commercialization of our diagnostic and therapeutic products. These risks are discussed
in detail under the “Risk Factors” discussion beginning on page 8 of this prospectus.

| 2 |